Glypican-1 Modulates the Angiogenic and Metastatic Potential of Human and Mouse Cancer Cells

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2007 Dec 8

PMID 18064304

Citations 94

Authors

Takuma Aikawa

Chery A Whipple

Martha E Lopez

Jason Gunn

Alison Young

Arthur D Lander

Murray Korc

Affiliations

Soon will be listed here.

Abstract

Cells isolated from many types of human cancers express heparin-binding growth factors (HBGFs) that drive tumor growth, metastasis, and angiogenesis. The heparan sulfate proteoglycan glypican-1 (GPC1) is a coreceptor for HBGFs. Here we show that both cancer cell-derived and host-derived GPC1 are crucial for efficient growth, metastasis, and angiogenesis of human and mouse cancer cells. Thus downregulation of GPC1 in the human pancreatic cancer cell line PANC-1, using antisense approaches, resulted in prolonged doubling times and decreased anchorage-independent growth in vitro as well as attenuated tumor growth, angiogenesis, and metastasis when these cells were transplanted into athymic mice. Moreover, athymic mice that lacked GPC1 exhibited decreased tumor angiogenesis and metastasis following intrapancreatic implantation with either PANC-1 or T3M4 human pancreatic cancer cells and fewer pulmonary metastases following intravenous injection of murine B16-F10 melanoma cells. In addition, hepatic endothelial cells isolated from these mice exhibited an attenuated mitogenic response to VEGF-A. These data indicate that cancer cell- and host-derived GPC1 are crucial for full mitogenic, angiogenic, and metastatic potential of cancer cells. Thus targeting GPC1 might provide new avenues for cancer therapy and for the prevention of cancer metastasis.

Citing Articles

Extracellular glypican-1 affects tumor progression and prognosis in esophageal cancer.

Shibata R, Konishi H, Arita T, Yamamoto Y, Matsuda H, Yamamoto T Cancer Med. 2024; 13(18):e70212.

PMID: 39300946 PMC: 11413415. DOI: 10.1002/cam4.70212.

Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis.

Li H, Chiang C, Kwak K, Wang X, Doddi S, Ramanathan L Adv Sci (Weinh). 2024; 11(11):e2306373.

PMID: 38204202 PMC: 10953589. DOI: 10.1002/advs.202306373.

A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.

Busato D, Capolla S, Durigutto P, Mossenta M, Bozzer S, Sblattero D J Transl Med. 2023; 21(1):864.

PMID: 38017492 PMC: 10685509. DOI: 10.1186/s12967-023-04745-9.

The Glycosaminoglycan Side Chains and Modular Core Proteins of Heparan Sulphate Proteoglycans and the Varied Ways They Provide Tissue Protection by Regulating Physiological Processes and Cellular Behaviour.

Farrugia B, Melrose J Int J Mol Sci. 2023; 24(18).

PMID: 37762403 PMC: 10531531. DOI: 10.3390/ijms241814101.

Silencing Glypican-1 enhances the antitumor effects of Pictilisib via downregulating PI3K/Akt/ERK signaling in chemo-resistant esophageal adenocarcinoma.

Pratap A, Qualman A, Garrett H, Westbrook L, The E, Mitra S Mol Cell Oncol. 2023; 10(1):2238873.

PMID: 37649964 PMC: 10464651. DOI: 10.1080/23723556.2023.2238873.

References

Kornmann M, Arber N, Korc M . Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest. 1998; 101(2):344-52. PMC: 508573. DOI: 10.1172/JCI1323. View

Korc M . Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer. 2003; 2:8. PMC: 149422. DOI: 10.1186/1476-4598-2-8. View

Kleeff J, Wildi S, Kumbasar A, Friess H, Lander A, Korc M . Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas. 1999; 19(3):281-8. DOI: 10.1097/00006676-199910000-00009. View

Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M . Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res. 2004; 10(2):581-90. DOI: 10.1158/1078-0432.ccr-0930-03. View

Chen R, Lander A . Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J Biol Chem. 2000; 276(10):7507-17. DOI: 10.1074/jbc.M008283200. View

Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y . Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999; 274(22):15732-9. DOI: 10.1074/jbc.274.22.15732. View

Kwak H, So J, Lee S, Kim I, Koh G . Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett. 1999; 448(2-3):249-53. DOI: 10.1016/s0014-5793(99)00378-6. View

Luo J, Guo P, Matsuda K, Truong N, Lee A, Chun C . Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer. 2001; 92(3):361-9. DOI: 10.1002/ijc.1202. View

Qiao D, Meyer K, Mundhenke C, Drew S, Friedl A . Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J Biol Chem. 2003; 278(18):16045-53. DOI: 10.1074/jbc.M211259200. View

10.

Vlodavsky I, Korner G, Bashkin P, Bar-Shavit R, Fuks Z . Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 1990; 9(3):203-26. DOI: 10.1007/BF00046361. View

11.

Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, Ron D . Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem. 1999; 274(16):10816-22. DOI: 10.1074/jbc.274.16.10816. View

12.

Yang Y, MacLeod V, Miao H, Theus A, Zhan F, Shaughnessy Jr J . Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem. 2007; 282(18):13326-33. DOI: 10.1074/jbc.M611259200. View

13.

Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellen L . Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell. 2006; 10(5):625-34. DOI: 10.1016/j.devcel.2006.03.009. View

14.

Carmeliet P, Jain R . Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801):249-57. DOI: 10.1038/35025220. View

15.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M . Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1):43-66. DOI: 10.3322/canjclin.57.1.43. View

16.

McKeehan W, Wang F, Kan M . The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998; 59:135-76. DOI: 10.1016/s0079-6603(08)61031-4. View

17.

Lee O, Xu J, Fueyo J, Fuller G, Aldape K, Alonso M . Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res. 2006; 4(12):915-26. DOI: 10.1158/1541-7786.MCR-06-0184. View

18.

Lobov I, Brooks P, Lang R . Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002; 99(17):11205-10. PMC: 123234. DOI: 10.1073/pnas.172161899. View

19.

Folkman J . Angiogenesis and apoptosis. Semin Cancer Biol. 2003; 13(2):159-67. DOI: 10.1016/s1044-579x(02)00133-5. View

20.

Lander A, Nie Q, Wan F . Do morphogen gradients arise by diffusion?. Dev Cell. 2002; 2(6):785-96. DOI: 10.1016/s1534-5807(02)00179-x. View